Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients (CAPRI)

Hsue et al., NCT04421404, CAPRI, NCT04421404, Aug 2021
Mortality -212% improvement lower risk ← → higher risk Mortality b -12% Ventilation -425% Progression, day 28 -425% primary Progression, day 14 -425% primary Conv. Plasma for COVID-19  CAPRI  LATE TREATMENT RCT Is late treatment with convalescent plasma beneficial? Double-blind RCT 34 patients in the USA (June 2020 - April 2021) Higher mortality (p=0.47) and ventilation (p=0.21), not sig. c19early.org Hsue et al., NCT04421404, August 2021 0 0.5 1 1.5 2+ RR
RCT 34 hospitalized patients in the USA, showing no significant difference with convalescent plasma treatment.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
Important missing comments or errors? Let us know.
risk of death, 212.5% higher, RR 3.12, p = 0.47, treatment 1 of 16 (6.2%), control 0 of 18 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 28.
risk of death, 12.5% higher, RR 1.12, p = 1.00, treatment 1 of 16 (6.2%), control 1 of 18 (5.6%), all cause, day 28.
risk of mechanical ventilation, 425.0% higher, RR 5.25, p = 0.21, treatment 2 of 16 (12.5%), control 0 of 18 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 28.
risk of progression, 425.0% higher, RR 5.25, p = 0.21, treatment 2 of 16 (12.5%), control 0 of 18 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), death or mechanical ventilation, day 28, primary outcome.
risk of progression, 425.0% higher, RR 5.25, p = 0.21, treatment 2 of 16 (12.5%), control 0 of 18 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), death or mechanical ventilation, day 14, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hsue et al., 23 Aug 2021, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, study period 9 June, 2020 - 30 April, 2021, trial NCT04421404 (history) (CAPRI).
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org December 2025 USA Russia Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines Spain Brazil Italy France Japan Canada China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org December 2025 USA Russia Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines Spain Brazil Italy France Japan Canada China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore New Zealand Malawi Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Serbia Syria USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0